SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 12, nr. 4, 2017
ISSN 1841-9038  |  e-ISSN 2069-6116
ISSN-L 1841-9038
CNCSIS - CMR - B+

HIGHLIGHTS

Plagiatul – in actualitate

Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

Committe on Publication Ethics

A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

Members Area


Tyrosine-kinase Inhibitors Treatment in Advanced Malignant Melanoma

and

ABSTRACT

Objective: To put in perspective recent advances in the treatment of malignant melanoma with novel tyrosine-kinase inhibitors.
Methods: We reviewed the largest trials that support the treatment with tyrosine-kinase inhibitors (TKIs) in cutaneous malignant melanoma, the base of the current guideline recommendations.
Conclusions: Mitogen-activated protein-kinase (MAPK) pathway inhibition via modern TKIs is a major breakthrough in the treatment of melanoma, with a very high benefit for patients with disease harboring BRAF-gene mutations, in terms of rates of response and survival.
Keywords: malignant melanoma, tyrosine-kinase inhibitors, BRAF mutation.

Full text | PDF